Skip to main content
Home
OUR XCHANGES
BY TOPIC
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY DRUG CONJUGATES THERAPEUTICS
ANTIBODY THERAPEUTICS
IMMUNOTHERAPIES
OLIGONUCLEOTIDE THERAPEUTICS
BY LOCATION
BOSTON, USA
SAN FRANCISCO, USA
MARYLAND, USA
SAN DIEGO, USA
PHILADELPHIA, USA
PAST EVENTS
INDUSTRY EXPERTS
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY DRUG CONJUGATES THERAPEUTICS
ANTIBODY THERAPEUTICS
IMMUNOTHERAPIES
OLIGONUCLEOTIDE THERAPEUTICS
NEWS XCHANGE
PARTNERSHIPS
OUR PARTNERS
BECOME A PARTNER
MEDIA PARTNERS
ABOUT US
GET TO KNOW US
MEET THE TEAM
GALLERY
CONTACT US
Home
OUR XCHANGES
BY TOPIC
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY DRUG CONJUGATES THERAPEUTICS
ANTIBODY THERAPEUTICS
IMMUNOTHERAPIES
OLIGONUCLEOTIDE THERAPEUTICS
BY LOCATION
BOSTON, USA
SAN FRANCISCO, USA
MARYLAND, USA
SAN DIEGO, USA
PHILADELPHIA, USA
PAST EVENTS
INDUSTRY EXPERTS
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY DRUG CONJUGATES THERAPEUTICS
ANTIBODY THERAPEUTICS
IMMUNOTHERAPIES
OLIGONUCLEOTIDE THERAPEUTICS
NEWS XCHANGE
PARTNERSHIPS
OUR PARTNERS
BECOME A PARTNER
MEDIA PARTNERS
ABOUT US
GET TO KNOW US
MEET THE TEAM
GALLERY
CONTACT US
Home
OUR XCHANGES
BY TOPIC
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY DRUG CONJUGATES THERAPEUTICS
ANTIBODY THERAPEUTICS
IMMUNOTHERAPIES
OLIGONUCLEOTIDE THERAPEUTICS
BY LOCATION
BOSTON, USA
SAN FRANCISCO, USA
MARYLAND, USA
SAN DIEGO, USA
PHILADELPHIA, USA
PAST EVENTS
INDUSTRY EXPERTS
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY DRUG CONJUGATES THERAPEUTICS
ANTIBODY THERAPEUTICS
IMMUNOTHERAPIES
OLIGONUCLEOTIDE THERAPEUTICS
NEWS XCHANGE
PARTNERSHIPS
OUR PARTNERS
BECOME A PARTNER
MEDIA PARTNERS
ABOUT US
GET TO KNOW US
MEET THE TEAM
GALLERY
CONTACT US
Industry Experts
Loading
Pedro de Jesus Cruz
Associate Director,
Merck
Sessions
24-Feb-2025
16:20– 17:20
Developing robust target validation in structural biology using AI
LinkedIn
YouTube
Search
Search
Search
Username *
Password *
Login